India approves revolutionary CAR-T cell therapy for Lymphoma and Leukemia treatment

Immunoadoptive Cell Therapy Private Limited (ImmunoACT), which is an associated company of Laurus Labs, has received official approval from the Central Drugs Standard Control Organization (CDSCO) for NexCAR19, India's first CAR-T cell therapy, designed for treating relapsed or refractory (r/r) B-cell lymphomas and leukemia.

 

This groundbreaking product, NexCAR19, is a result of an extensive decade-long collaboration between IIT Bombay and Tata Memorial Centre, aimed at delivering high-quality and affordable CAR-T cell therapy to all sections of society. Clinical trials have shown a remarkable 70% overall response rate with an excellent safety profile. NexCAR19 is expected to greatly benefit clinical management in resource-constrained settings.

 

Dr. Rahul Purwar, Founder & CEO of ImmunoACT, expressed the importance of this achievement, stating that it puts India on the list of countries with access to CAR-T therapy.

 

This milestone has been supported by Laurus Labs Limited, a pharmaceutical and biotechnology leader, with investments exceeding USD 18 million. Tata Memorial Centre has played a pivotal role in the clinical studies.

 

The approval of NexCAR19 marks a significant leap forward in the fight against blood cancers, ensuring more accessible and affordable treatment for patients in India. ImmunoACT is dedicated to making this therapy available to partner hospitals as soon as possible.

Top stories
Budget

Impact of Budget on Common Man

9 mins read . 23 Jul 2024 . 12:22 PM

Budget

Finance Minister Nirmala Sitharaman to Presents Union Budget 2024

3 mins read . 23 Jul 2024 . 09:20 AM

Company

JSW Energy Arm Secures Major Solar and Energy Storage Projects

5 mins read . 23 Jul 2024 . 05:35 AM

Related Blogs
blog-logo

Share Market

blog-logo

8 mins read . 19 Jul 2024

Stock Market Trading Time in India

  • 38 people read
blog-logo

Share Market

blog-logo

11 mins read . 19 Jul 2024

How To Trade in T2T Stocks

  • 38 people read
Kickstart your equities journey today You've got this
By submitting this I agree to the terms & conditions